S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
The perfect AI stock under $10 (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
The perfect AI stock under $10 (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
The perfect AI stock under $10 (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
The perfect AI stock under $10 (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
66,000% upside on tiny biotech? (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
66,000% upside on tiny biotech? (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
NASDAQ:ABEO

Abeona Therapeutics (ABEO) Stock Price, News & Analysis

$6.70
-0.05 (-0.74%)
(As of 02/22/2024 ET)
Today's Range
$6.61
$6.99
50-Day Range
$4.07
$7.01
52-Week Range
$2.19
$7.50
Volume
241,227 shs
Average Volume
280,757 shs
Market Capitalization
$165.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.00

Abeona Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
467.2% Upside
$38.00 Price Target
Short Interest
Healthy
3.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.03
Upright™ Environmental Score
News Sentiment
0.42mentions of Abeona Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$36,199 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.04) to ($1.76) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.21 out of 5 stars

Medical Sector

144th out of 934 stocks

Pharmaceutical Preparations Industry

55th out of 419 stocks


ABEO stock logo

About Abeona Therapeutics Stock (NASDAQ:ABEO)

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

ABEO Stock Price History

ABEO Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Abeona Therapeutics Inc
Abeona Therapeutics (NASDAQ:ABEO) Lowered to Sell at StockNews.com
ABEO Apr 2024 7.500 call
ABEO Mar 2024 10.000 call
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Abeona Therapeutics Inc (ABEO)
Abeona Therapeutics Inc PCJ
Abeona Therapeutics stock climbs on FDA Priority Review
See More Headlines
Receive ABEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
2/22/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ABEO
Previous Symbol
OTCMKTS:ACCP
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.00
High Stock Price Target
$38.00
Low Stock Price Target
$38.00
Potential Upside/Downside
+467.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-39,700,000.00
Pretax Margin
-1,253.31%

Debt

Sales & Book Value

Annual Sales
$3.57 million
Book Value
$1.56 per share

Miscellaneous

Free Float
23,955,000
Market Cap
$165.98 million
Optionable
Optionable
Beta
1.33

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report














ABEO Stock Analysis - Frequently Asked Questions

Should I buy or sell Abeona Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ABEO shares.
View ABEO analyst ratings
or view top-rated stocks.

What is Abeona Therapeutics' stock price target for 2024?

1 equities research analysts have issued 1-year price objectives for Abeona Therapeutics' shares. Their ABEO share price targets range from $38.00 to $38.00. On average, they predict the company's share price to reach $38.00 in the next twelve months. This suggests a possible upside of 467.2% from the stock's current price.
View analysts price targets for ABEO
or view top-rated stocks among Wall Street analysts.

How have ABEO shares performed in 2024?

Abeona Therapeutics' stock was trading at $5.01 at the beginning of 2024. Since then, ABEO shares have increased by 33.7% and is now trading at $6.70.
View the best growth stocks for 2024 here
.

Are investors shorting Abeona Therapeutics?

Abeona Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 778,500 shares, an increase of 17.6% from the January 15th total of 662,100 shares. Based on an average daily trading volume, of 223,900 shares, the short-interest ratio is currently 3.5 days. Approximately 3.3% of the shares of the company are sold short.
View Abeona Therapeutics' Short Interest
.

When is Abeona Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our ABEO earnings forecast
.

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) posted its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($4.00) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($4.00).

When did Abeona Therapeutics' stock split?

Shares of Abeona Therapeutics reverse split before market open on Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Abeona Therapeutics own?
Who are Abeona Therapeutics' major shareholders?

Abeona Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.45%), AIGH Capital Management LLC (3.18%), Point72 Asset Management L.P. (3.07%), Worth Venture Partners LLC (0.79%), Barclays PLC (0.69%) and Northern Trust Corp (0.53%). Insiders that own company stock include Brendan M O'malley, Christine Berni Silverstein, Edward Carr, Joseph Walter Vazzano, Mark Alvino, Michael Amoroso, Sco Capital Partners Llc, Todd Wider and Vishwas Seshadri.
View institutional ownership trends
.

How do I buy shares of Abeona Therapeutics?

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABEO) was last updated on 2/23/2024 by MarketBeat.com Staff